Nerlynx União Europeia - polonês - EMA (European Medicines Agency)

nerlynx

pierre fabre medicament - neratinib - nowotwory piersi - Środki przeciwnowotworowe - nerlynx wskazany w rozszerzonej adjuvant terapii dorosłych pacjentów z wczesnym stadium hormonu receptor her2 pozytywnym i-wyraził/wzmocniony raka piersi i które co najmniej jednego roku od zakończenia budowy do adjuvant terapii trastuzumabom.

Impulsor União Europeia - polonês - EMA (European Medicines Agency)

impulsor

pierre fabre medicament - milnacipran - fibromialgia

Ebvallo União Europeia - polonês - EMA (European Medicines Agency)

ebvallo

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Hemangiol União Europeia - polonês - EMA (European Medicines Agency)

hemangiol

pierre fabre medicament - chlorowodorek propranololu - naczyniak krwionośny - leki beta-adrenolityczn - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

Ribomunyl 0,525 mg + 1,875 mg Tabletki Polônia - polonês - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

ribomunyl 0,525 mg + 1,875 mg tabletki

pierre fabre medicament polska sp. z o.o. - proteoglikany + rybosomy bakteryjne - tabletki - 0,525 mg + 1,875 mg